LOW TOTAL TP42/40 PLASMA RATIO IN aMCI PATIENTS IS ASSOCIATED WITH A FDG-PET PATTERN SUGGESTIVE OF AD AND PREDICTS PROGRESSION TO DEMENTIA

23/10/2017

(1) Araclon Biotech S.L., Zaragoza, Spain
(2) Clínica Universitaria de Pamplona, Pamplona, Spain
(3) Fundación CITA-Alzheimer, San Sebastián, Spain.
(4) Fundació ACE. Barcelona Alzheimer Treatment and Research Center. Barcelona, Spain.
(5) www.araclon.com

Del 1 al 23/10/2017

Congreso: CTAD Boston 2017

Autores: Virginia Pérez-Grijalba1, Judith Romero1, Pedro Pesini, 1 Leticia Sarasa1, Itziar San-José1, Javier Arbizu2, Pablo Martínez-Lage3, Lluis Tárraga4, Agustín Ruiz4, Mercè Boada4, Manuel Sarasa1 and The AB255 Araclon Group5

Ver PDF